Thrive Earlier Detection, the developer of an early cancer screening blood test invented at JHU and backed by Exact Sciences and Blue Cross and Blue Shield Association, has raised $257m in series B funding.

Thrive Earlier Detection, a US-based cancer screening technology developer backed by corporates Blue Cross and Blue Shield Association and Exact Sciences., collected $257m yesterday in a series B round co-led by Casdin Capital and Section 32. Bain Capital Life Sciences, a subsidiary of private equity firm Bain Capital, also invested, as did Brown Advisory, Driehaus…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.